ESR1 and neoplasm: By enriching the clinical variables with biomarker information, namely estrogen receptor and L1 cell adhesion molecule expression status indicators, peritoneal washing status and tumor size < 5 cm, we improve the discrimination and calibration performance of the CPH and OST models.